5th Gene Therapy for Opthalmic Disorders Summit

This extensive three-day event will tackle obstacles spanning preclinical and clinical development. From engineering AAVs and innovating vectors for enhanced delivery and transduction to specific target cells, to confirming suitable clinical endpoints that demonstrate efficacy, all facets will be covered.

Drawing in teams from R&D, preclinical, and clinical development sectors of prominent biotech and pharmaceutical companies, this gathering offers a chance to gain insights into successful strategies shared by those with first-hand experience in developing ocular gene therapies.